Here, we demonstrate that low expression of CYLD is associated with a poor prognosis of (ABC) DLBCL and MCL patients, and that chronic BCR signaling controls cleavage-mediated inactivation of CYLD by the paracaspase MALT1, followed by rapid proteasomal degradation. The gene discussed is MALT1; the disease is mantle cell lymphoma.